Home > Research > Publications & Outputs > The global prevalence of hepatitis D virus infe...

Research

Associated organisational unit

Electronic data

  • PIIS0168827820302208

    Accepted author manuscript, 8.99 MB, PDF document

    Available under license: CC BY: Creative Commons Attribution 4.0 International License

Links

Text available via DOI:

View graph of relations

The global prevalence of hepatitis D virus infection: systematic review and metaanalysis

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

The global prevalence of hepatitis D virus infection: systematic review and metaanalysis. / Stockdale, Alexander J.; Kreuels, Benno; Henrion, Marc R. Y. et al.
In: Journal of Hepatology, Vol. 73, No. 3, 01.09.2020, p. 523-532.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Stockdale, AJ, Kreuels, B, Henrion, MRY, Giorgi, E, Kyomuhangi, I, de Martel, C, Hutin, Y & Geretti, AM 2020, 'The global prevalence of hepatitis D virus infection: systematic review and metaanalysis', Journal of Hepatology, vol. 73, no. 3, pp. 523-532. https://doi.org/10.1016/j.jhep.2020.04.008

APA

Stockdale, A. J., Kreuels, B., Henrion, M. R. Y., Giorgi, E., Kyomuhangi, I., de Martel, C., Hutin, Y., & Geretti, A. M. (2020). The global prevalence of hepatitis D virus infection: systematic review and metaanalysis. Journal of Hepatology, 73(3), 523-532. https://doi.org/10.1016/j.jhep.2020.04.008

Vancouver

Stockdale AJ, Kreuels B, Henrion MRY, Giorgi E, Kyomuhangi I, de Martel C et al. The global prevalence of hepatitis D virus infection: systematic review and metaanalysis. Journal of Hepatology. 2020 Sept 1;73(3):523-532. Epub 2020 Apr 23. doi: 10.1016/j.jhep.2020.04.008

Author

Stockdale, Alexander J. ; Kreuels, Benno ; Henrion, Marc R. Y. et al. / The global prevalence of hepatitis D virus infection : systematic review and metaanalysis. In: Journal of Hepatology. 2020 ; Vol. 73, No. 3. pp. 523-532.

Bibtex

@article{79daf8499f534a55847431cdb89a3814,
title = "The global prevalence of hepatitis D virus infection: systematic review and metaanalysis",
abstract = "Background and AimsThere are uncertainties about the epidemic patterns of hepatitis delta virus (HDV) infection and its contribution to the burden of liver disease. We estimated the global prevalence of HDV infection and explored its contribution to the development of cirrhosis and hepatocellular carcinoma (HCC) among hepatitis B surface antigen (HBsAg)-positive people.MethodsWe searched Pubmed, EMBASE and Scopus for studies reporting on total or IgG anti-HDV among HBsAg-positive people. Anti-HDV prevalence was estimated using a binomial mixed model, weighting for study quality and population size. The population attributable fraction (PAF) of HDV to cirrhosis and HCC among HBsAg-positive people was estimated using random-effects models.ResultsWe included 282 studies, comprising 376 population samples from 95 countries, which together tested 120,293 HBsAg-positive people for anti-HDV. The estimated anti-HDV prevalence was 4.5% (95% CI 3.6, 5.7) among all HBsAg-positive people and 16.4% (14.6, 18.6) among those attending hepatology clinics. Worldwide, 0.16% (0.11, 0.25) of the general population, totalling 12.0 (8.7, 18.7) million people, were estimated to be anti-HDV positive. Prevalence among HBsAg-positive people was highest in Mongolia, the Republic of Moldova and countries in Western and Middle Africa, and was higher in injecting drug users, haemodialysis recipients, men who have sex with men, commercial sex workers, and those with hepatitis C virus or HIV. Among HBsAg-positive people, preliminary PAF estimates of HDV were 18% (10, 26) for cirrhosis and 20% (8, 33) for HCC.ConclusionsAn estimated 12 million people worldwide have experienced HDV infection, with higher prevalence in certain geographic areas and populations. HDV is a significant contributor to HBV-associated liver disease. More quality data are needed to improve the precisions of burden estimates.",
author = "Stockdale, {Alexander J.} and Benno Kreuels and Henrion, {Marc R. Y.} and Emanuele Giorgi and Irene Kyomuhangi and {de Martel}, Catherine and Yvan Hutin and Geretti, {Anna Maria}",
year = "2020",
month = sep,
day = "1",
doi = "10.1016/j.jhep.2020.04.008",
language = "English",
volume = "73",
pages = "523--532",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - The global prevalence of hepatitis D virus infection

T2 - systematic review and metaanalysis

AU - Stockdale, Alexander J.

AU - Kreuels, Benno

AU - Henrion, Marc R. Y.

AU - Giorgi, Emanuele

AU - Kyomuhangi, Irene

AU - de Martel, Catherine

AU - Hutin, Yvan

AU - Geretti, Anna Maria

PY - 2020/9/1

Y1 - 2020/9/1

N2 - Background and AimsThere are uncertainties about the epidemic patterns of hepatitis delta virus (HDV) infection and its contribution to the burden of liver disease. We estimated the global prevalence of HDV infection and explored its contribution to the development of cirrhosis and hepatocellular carcinoma (HCC) among hepatitis B surface antigen (HBsAg)-positive people.MethodsWe searched Pubmed, EMBASE and Scopus for studies reporting on total or IgG anti-HDV among HBsAg-positive people. Anti-HDV prevalence was estimated using a binomial mixed model, weighting for study quality and population size. The population attributable fraction (PAF) of HDV to cirrhosis and HCC among HBsAg-positive people was estimated using random-effects models.ResultsWe included 282 studies, comprising 376 population samples from 95 countries, which together tested 120,293 HBsAg-positive people for anti-HDV. The estimated anti-HDV prevalence was 4.5% (95% CI 3.6, 5.7) among all HBsAg-positive people and 16.4% (14.6, 18.6) among those attending hepatology clinics. Worldwide, 0.16% (0.11, 0.25) of the general population, totalling 12.0 (8.7, 18.7) million people, were estimated to be anti-HDV positive. Prevalence among HBsAg-positive people was highest in Mongolia, the Republic of Moldova and countries in Western and Middle Africa, and was higher in injecting drug users, haemodialysis recipients, men who have sex with men, commercial sex workers, and those with hepatitis C virus or HIV. Among HBsAg-positive people, preliminary PAF estimates of HDV were 18% (10, 26) for cirrhosis and 20% (8, 33) for HCC.ConclusionsAn estimated 12 million people worldwide have experienced HDV infection, with higher prevalence in certain geographic areas and populations. HDV is a significant contributor to HBV-associated liver disease. More quality data are needed to improve the precisions of burden estimates.

AB - Background and AimsThere are uncertainties about the epidemic patterns of hepatitis delta virus (HDV) infection and its contribution to the burden of liver disease. We estimated the global prevalence of HDV infection and explored its contribution to the development of cirrhosis and hepatocellular carcinoma (HCC) among hepatitis B surface antigen (HBsAg)-positive people.MethodsWe searched Pubmed, EMBASE and Scopus for studies reporting on total or IgG anti-HDV among HBsAg-positive people. Anti-HDV prevalence was estimated using a binomial mixed model, weighting for study quality and population size. The population attributable fraction (PAF) of HDV to cirrhosis and HCC among HBsAg-positive people was estimated using random-effects models.ResultsWe included 282 studies, comprising 376 population samples from 95 countries, which together tested 120,293 HBsAg-positive people for anti-HDV. The estimated anti-HDV prevalence was 4.5% (95% CI 3.6, 5.7) among all HBsAg-positive people and 16.4% (14.6, 18.6) among those attending hepatology clinics. Worldwide, 0.16% (0.11, 0.25) of the general population, totalling 12.0 (8.7, 18.7) million people, were estimated to be anti-HDV positive. Prevalence among HBsAg-positive people was highest in Mongolia, the Republic of Moldova and countries in Western and Middle Africa, and was higher in injecting drug users, haemodialysis recipients, men who have sex with men, commercial sex workers, and those with hepatitis C virus or HIV. Among HBsAg-positive people, preliminary PAF estimates of HDV were 18% (10, 26) for cirrhosis and 20% (8, 33) for HCC.ConclusionsAn estimated 12 million people worldwide have experienced HDV infection, with higher prevalence in certain geographic areas and populations. HDV is a significant contributor to HBV-associated liver disease. More quality data are needed to improve the precisions of burden estimates.

U2 - 10.1016/j.jhep.2020.04.008

DO - 10.1016/j.jhep.2020.04.008

M3 - Journal article

VL - 73

SP - 523

EP - 532

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 3

ER -